Andrei Carvalho Sposito
Andrei Carvalho Sposito
This is a Phase 1, multi-center, dose escalation study that is followed by a Phase 2 randomized, double-blind, placebo-controlled study of the safety and efficacy of WP1122 administered q12h ±1 hr PO in adult patients with COVID-19 who require hospitalization with respiratory support. The Phase 1 component will enroll COVID-19 positive patients who are symptomatic and the Phase 2 component will enroll adults with COVID-19 who require hospitalization for respiratory support and those patients requiring intubation with mechanical ventilation.
COVID-19
Mechanical Ventilation Complication
COVID-19 Acute Respiratory Distress Syndrome
WP1122
Phase 1
Phase 2
Study Type : | Interventional |
Estimated Enrollment : | 75 participants |
Masking : | Triple |
Primary Purpose : | Treatment |
Official Title : | A Phase 1/2, Dose Escalation, and Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Oral WP1122 in Adult Patients With Advanced Coronavirus Disease 2019 (COVID-19) |
Actual Study Start Date : | December 2022 |
Estimated Primary Completion Date : | February 2023 |
Estimated Study Completion Date : | October 2023 |
Arm | Intervention/treatment |
---|---|
Experimental: WP1122 Experimental drug with Concentration 100mg/mL - administered q12h PO for 10 days |
Drug: WP1122 |
Placebo Comparator: placebo Placebo Administered q12h PO for 10 days |
Drug: WP1122 |
Ages Eligible for Study: | 18 Years |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.
Not yet recruiting
University of Campinas
Campinas, SP, Brazil, 13083-887